Stelara 90 MG/ML syringeml
Ended Awarded Last action
- Contract number
- SPE2DR26FFBV6
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $33,168
Award facts
- Contract value 100% obligated
- $33,168.26 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency (DLA) awarded a delivery order valued at $33,168.26 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Stelara 90 mg/ml syringes. This firm fixed-price delivery order, issued on January 8, 2026, with an ultimate completion date of January 30, 2026, carries no set-aside designation, demonstrating the contractor's competitive capability in unrestricted federal procurement. DMS Pharmaceutical Group Inc. will perform the work at its Park Ridge facility.
This delivery order is issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract (IDC) with the DLA's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $499.9 million contract awarded on November 13, 2025, with a completion date of December 31, 2036. The PPV-G GEN V program is part of the DLA's broader $30.3 billion pharmaceutical supply strategy designed to provide Department of Defense military healthcare facilities with a comprehensive range of pharmaceutical products and medical consumables on a recurring basis. As a prime vendor contractor under this initiative, DMS Pharmaceutical Group serves as a critical supplier supporting DOD healthcare operations globally, and the issuance of this delivery order reflects the company's established performance capability in fulfilling specialized pharmaceutical requirements for the federal military medical system.
Quick answers
Who was awarded contract SPE2DR26FFBV6?
SPE2DR26FFBV6 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on January 8, 2026.
How much is contract SPE2DR26FFBV6 worth?
The government has obligated $33,168 on SPE2DR26FFBV6.
Is contract SPE2DR26FFBV6 an order under another contract?
Yes. SPE2DR26FFBV6 is a delivery order under SPE2DR25D9239, an indefinite delivery contract.
Was contract SPE2DR26FFBV6 competed?
The extent of competition for SPE2DR26FFBV6 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award